The 2026 Dermatology Medicare Update: What Dermatology Practices Need to Know

The Medicare conversion factor rose to $33.40 for non-qualifying practices and $33.57 for qualifying APM participants, up from $32.35. A 2.5 per cent efficiency adjustment lowered the work RVUs on the procedure codes dermatology depends on, so many practices will see flat or lower pay despite the higher factor. CPT documentation rules tightened for biopsies, lesion destruction, and Mohs. Medicare cut skin substitute payment to a flat $127.14 per square centimetre for most products. The practices that protect their margin in 2026 are the ones that read their pay at the code level and fix documentation at the provider level.

The 2026 Medicare Physician Fee Schedule put dermatology in an odd spot. The headline was good news, because after years of cuts and flat updates CMS raised the conversion factor. But once practices opened the specialty impact tables and the code level changes, the picture turned more complicated. The same final rule that raised the factor also lowered the value of the procedure codes that drive most dermatology revenue.

That makes the headline number almost useless on its own. A practice with heavy evaluation and management volume gains from the higher factor. A procedure heavy practice running hundreds of biopsies and excisions a week can lose ground, because the efficiency adjustment erodes the per procedure value even as the factor rises. 

This guide walks through every change that matters, the corrected numbers, the documentation rules that decide whether you get paid, and the steps that protect your margin. It is written for dermatology medical billing teams and practice owners, from solo offices to multi location groups.

The 2026 conversion factor, the real story behind the number 

CMS finalized two conversion factors for 2026. Non qualifying practices, which is most of dermatology, use $33.40. Qualifying APM participants use $33.57. Both rose from the 2025 rate of $32.35, a 3.26 percent and a 3.77 percent increase. After several flat or negative years, an increase is welcome.

A higher factor does not lift every code, though. Medicare pays you by multiplying the total RVUs for a code by the conversion factor. When CMS lowers those RVUs at the same time it raises the factor, the increase can be partly or fully cancelled. That is what happened for 2026. The 2.5 percent increase came from the One Big Beautiful Bill Act. CMS also applied a 2.5 percent efficiency adjustment that cut the work RVUs on non time based procedure codes. Biopsies, excisions, and lesion destruction, the core of dermatology revenue, are all non time based procedure codes, so they took the cut directly.

The takeaway is simple. Do not plan your 2026 budget off the headline factor. Pull your top 20 codes by volume, apply the 2026 RVUs from the CMS Physician Fee Schedule Look Up Tool, and calculate the real rate for each one. That code level number tells you where you stand. The factor percentage does not.

The site of service shift that hits office based dermatology

One 2026 change sits underneath the headlines and deserves attention. CMS finalized a new practice expense method that creates a payment difference between office and facility settings. Starting in 2026, the agency cut the share of facility practice expense RVUs allocated on work RVUs to half the share used for the non facility setting. CMS framed this as recognizing the higher indirect costs of office based practices.

For dermatology this matters because so much of the specialty runs on practice expense, the supplies, equipment, and clinical staff time behind each procedure. Two practices billing the same code can see different economics depending on where the service is delivered and how their costs are structured. Office based dermatology relies on non facility payment, which carries the practice expense load. Practices with provider based or hospital affiliated sites should model both settings, because the facility and non facility values moved differently for 2026. Know which of your services are delivered where, and which codes carry the heaviest practice expense, before you project the year.

CPT changes every dermatology biller must know

The AMA released more than 400 CPT changes for 2026. Most do not touch dermatology, but the ones that do hit your highest volume services. Miss them and you invite rejections, downcoding, and audit exposure.

Biopsy code changes and the new measurement rule 

The technique based framework held. Tangential biopsies, which include shave, scoop, saucerize, and curette, use 11102 as the base and 11103 for each additional lesion. Punch biopsies use 11104 and 11105. Incisional biopsies use 11106 and 11107. What changed is the documentation standard. The 2026 descriptors make it explicit that you must record lesion size before anesthesia. If staff injects the local block first, the tissue distorts and the measurement becomes unreliable, which is both a clinical problem and an audit flag. Make pre anesthesia measurement a required, documented step on every biopsy. One financial note worth knowing. When either technique is clinically appropriate, punch biopsies carry a higher work RVU than tangential, so the choice has a revenue effect across a high volume schedule. Confirm the exact RVU values in the 2026 fee schedule file before you build that into policy.

Lesion destruction codes and the new method rule 

The families covering 17000 through 17004 for premalignant lesions and 17110 through 17111 for benign lesions now require you to document the destruction method. Your note must state whether the lesion was treated with cryosurgery, electrosurgery, laser, or chemical. Payers use that method of documentation to test medical necessity, especially for lasers, where the cosmetic question gets the most scrutiny. 

A note that says lesion destroyed, with no method, no lesion type, and no clinical indication, hands the payer the ambiguity it needs to call the service cosmetic and deny it. For premalignant lesions, document the actinic keratosis diagnosis with the ICD-10 code, the method, the number of lesions, and the rationale. For benign lesions, make the medical indication explicit, and keep any aesthetic comment the patient made out of the procedure note.

Mohs surgery documentation and coding 

Mohs is one of the most scrutinized procedures in Medicare, and 2026 added two documentation requirements. First, the pathology report must now align with College of American Pathologists standards, documenting tissue orientation, the number of sections examined, and confirmation of clear margins, before reconstruction codes can be billed on the same date. If your reports miss any of the three, same date reconstruction is at risk. 

Second, the descriptor states that the operating surgeon must personally perform or directly supervise the tissue processing and histologic exam at each stage. If anyone other than the operating surgeon interpreted the histology without direct supervision, the claim structure is exposed. Coding stays stage based. 17311 covers the first stage for head, neck, hands, feet, genitalia, or any single stage case. 17313 covers the first stage for trunk, arms, and legs. 

Add-on codes 17312 and 17314 apply to each additional stage, and 17315 covers additional tissue blocks beyond the first five. Bill repairs separately and match them to the repair type in the operative note. Most commercial payers and a growing number of Medicare Advantage plans require prior authorization for Mohs, so verify before you schedule.

It helps to keep a current desk reference so coders are not working from a 2025 superbill, which is what our “dermatology billing cheat sheet” is built for. 

Modifier 25 and the same day E/M question

Modifier 25 is the most audited modifier in dermatology, and 2026 raises the stakes because payers are running more automated review on these claims. Use modifier 25 when you perform a significant, separately identifiable evaluation and management service on the same day as a procedure. The classic example is a patient seen for a new or worsening condition who also has a lesion treated at the same visit. The E/M has to stand on its own in the chart, documented independently from the procedure, or it gets bundled and denied.

Two patterns draw audits. Appending modifier 25 to nearly every procedure encounter signals a problem, and payers flag practices whose 25 usage runs high across procedure days. Billing an E/M for the routine, expected work that surrounds a planned procedure, with no separate condition, is the kind of claim post payment audits recover. When a biopsy and a destruction or excision happen on the same lesion at the same visit, the biopsy is usually bundled, so code the definitive procedure, not both. Clean modifier 25 discipline is one of the highest return habits a dermatology practice can build in 2026.

The 2026 ICD-10-CM update

Coding accuracy in 2026 also depends on the diagnosis side. The FY2026 ICD-10-CM update took effect October 1, 2025 and added a large set of new codes, including expanded options for psoriasis, eczema, and actinic keratosis. Update your problem lists, EHR favorites, and superbills so the diagnosis you report matches the new granularity. Vague or unspecified diagnoses are a fast path to downcoding and denials, especially when they fail to support the medical necessity of a procedure on the same claim.

The skin substitute overhaul, the biggest payment change in 2026

If your practice runs a wound care or limb salvage line and uses skin substitute products, this is the change that hits hardest. The 2026 rule made the largest change to skin substitute payment in the history of the program.

What changed.

Before 2026, most skin substitutes were treated as biologicals and paid under the average sales price plus 6 percent method, where high cost products could pay several hundred to several thousand dollars per square centimeter. Effective January 1, 2026, CMS reclassified most skin substitutes as incident to supplies rather than biologicals. Under the new method, Medicare pays a single flat rate for most products, regardless of brand or acquisition cost. The final rule set that rate at $127.28 per square centimeter, and a technical correction on November 26, 2025 revised it to $127.14 per square centimeter. The product is not separately payable on its own. It is only reimbursed when applied during a covered application procedure, such as the 15271 through 15278 family.

Which products keep ASP.

CMS grouped products into PMA, 510(k), and 361 HCT/P categories, and for 2026 all three receive the same flat rate, with separate rates planned for later years. Products licensed as biologicals under Section 351 of the Public Health Service Act keep the average sales price plus 6 percent method. Those true biologic license products are a small part of the market.

What This Means for Your Practice?

First, identify whether your inventory is 361 HCT/P, which now gets the flat rate, or Section 351 biologicals, which keep ASP. That answer sets your model for each product. Second, compare your acquisition cost to $127.14. If a product costs you more than the flat rate, you lose money on every application to a Medicare patient, so a product by product analysis is not optional. Third, the waste rules changed. For these reclassified products you bill only what you apply. Modifier JW for discarded drug, and modifier JZ for no waste, no longer apply to them, because they are no longer drugs or biologicals. JW and JZ still apply to the Section 351 biologicals that keep ASP. 

Document the ulcer type and measurements, photographs, wound duration, conservative care and response, and treatment intervals, because CMS is launching the Wound Integrity and Sustainability of Evidence Review model in pilot states in 2026 to target skin substitute waste. Note as well that CMS withdrew the finalized wound care coverage determinations in December 2025, so confirm the current local coverage rules before you bill.

Practices with a heavier wound care line often separate this into a dedicated wound care billing workflow, since the 2026 rules differ so much from standard dermatology claims. 

Dermatology CPT code rates for 2026 

In the table below, there are approximate non-facility Medicare reimbursement rates for common dermatology codes in 2026. 

All rates reflect the $33.40 conversion factor and finalized RVU values. Rates vary by geographic locality.

Evaluation and Management

Biopsy Codes

Lesion Destruction

Excision Codes (Trunk, Arms, Legs)

Mohs Surgery

All rates are approximate national non-facility averages based on the $33.40 conversion factor. Verify current rates using the CMS PFS Look-Up Tool at cms.gov.

Commonly under captured dermatology services

Tight payment years reward practices that capture everything they legitimately earn. Dermatology routinely under bills a few services. Dermoscopy is often performed but not consistently captured. Medically necessary photodynamic therapy and UV based phototherapy are sometimes documented in a way that does not support the claim. Intralesional injections and the drug supply behind them can be missed. None of this is about billing more than you did. It is about making sure the documentation captures the work you already performed, so it becomes payable. A quick audit of these specific services often finds revenue your current workflow is leaving behind.

MIPS in 2026, what dermatologists need to do

MIPS continues in 2026, with the payment adjustment applied two years later to 2028 Medicare payments. You are a required participant if you exceed all three low volume thresholds in the performance year, which are more than $90,000 in Part B allowed charges, more than 200 Medicare Part B patients, and more than 200 covered professional services. Fall below any one of the three and you are excluded, though you may be able to opt in.

The 2026 performance year carries a maximum positive adjustment of 9 percent and a maximum negative adjustment of 9 percent, with the performance threshold held at 75 points. For a dermatology group with real Medicare volume, a negative adjustment stacked on the efficiency adjustment and the skin substitute change is meaningful pressure. 

Two moves help. First, look at MIPS Value Pathways, the streamlined reporting tracks CMS is steering specialties toward, and decide whether a pathway fits your group better than traditional MIPS. 

Second, treat E/M documentation as a revenue strategy, not a compliance chore. High complexity medical decision making supports 99215, moderate supports 99214, and many dermatologists default to 99213 out of habit even when the visit qualifies higher. 

Because E/M codes are exempt from the efficiency adjustment that cut your procedure codes, accurate E/M leveling is one of the most effective revenue protections in 2026. The G2211 visit complexity add-on can apply to longitudinal E/M care as well, so confirm where it fits your encounters.

Revenue Protection Strategies for Dermatology Practices in 2026

The practices that come through reimbursement pressure best fix documentation at the provider level, not just the billing level. Coders can only bill what the note supports. If the chart does not state the destruction method, the pre anesthesia measurement, the biopsy technique, or the findings that prove medical necessity, no amount of billing skill recovers it.

Run a 50 claim internal audit in January, pulled from your highest volume codes. Confirm the documentation supports the billed code, that measurements are present on biopsy and excision claims, that destruction notes name the method, and that Mohs pathology reports meet the new CAP elements. A problem caught in January costs you one corrected claim. The same problem found in a post payment audit costs you a recoupment, interest, and compliance risk. Then look outward. Commercial payers benchmark off Medicare, so the 2026 changes tend to reach commercial reimbursement within roughly 60 to 90 days. If you have not renegotiated your commercial fee schedules against the updated Medicare rates, you are likely leaving money on the table.

What large and multi location dermatology groups should do

Bigger groups have more exposure and more leverage. The exposure comes from volume, since every per code change multiplies across providers and sites, and from the site of service shift, which lands harder on provider based and hospital affiliated locations. The leverage comes from scale. 

A multi location group can model the specialty impact across its full code mix, standardize procedure note templates and superbills across every provider so documentation is consistent, and report MIPS at the group level where that produces a better score. Scale also strengthens payer negotiations, because a group that can show its top procedure volumes against the Medicare baseline has real grounds to renegotiate commercial contracts. For these organizations the single highest value 2026 project is a code level impact model built on their own utilization, paired with a documentation governance standard every provider follows.

Groups that would rather not build and run that in house often hand it to a partner for dermatology revenue cycle management as a standing service.

Frequently asked questions

What is the 2026 Medicare conversion factor for dermatology?

For 2026 it is $33.40 for non qualifying practices and $33.57 for qualifying APM participants, up from $32.35 in 2025. Most dermatology practices use the $33.40 rate. A higher factor does not guarantee higher pay, because the efficiency adjustment lowered the RVUs on many procedure codes.

How much does Medicare pay for skin substitutes in 2026?

Medicare now pays a single flat rate for most skin substitute products, set at $127.28 in the final rule and revised to $127.14 per square centimeter by a November 2025 technical correction. The product is only payable when applied during a covered application procedure. Products licensed as Section 351 biologicals keep the older average sales price plus 6 percent method.

What CPT changes affect dermatology in 2026?

The biggest changes are documentation requirements. Biopsy codes 11102 through 11107 require lesion size recorded before anesthesia. Lesion destruction codes require the method to be documented. Mohs codes added pathology and supervision requirements. The codes themselves are largely held, but claims that miss the new documentation standard are at risk of denial.

Does the conversion factor increase mean higher dermatology pay?

Not necessarily. The 2.5 percent efficiency adjustment reduced the work RVUs on non time based procedure codes, which are the core of dermatology. Procedure heavy practices can see flat or lower pay, while practices with strong E/M volume benefit more, since E/M codes are exempt from the adjustment.

Who has to participate in MIPS in 2026?

You are required to participate if you exceed all three low volume thresholds, more than $90,000 in Part B allowed charges, more than 200 Part B patients, and more than 200 covered professional services. The 2026 performance year affects 2028 payments, with adjustments up to plus or minus 9 percent.